Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers
暂无分享,去创建一个
A. Iafrate | J. Reis-Filho | B. Weigelt | J. Golfinos | S. Dogan | M. Snuderl | A. Tsirigos | E. Sulman | Seema Patel | D. Zagzag | A. Kloetgen | J. Stafford | A. Chi | J. Serrano | D. Placantonakis | E. Sulman | S. Chiang | R. Bledea | V. Vasudevaraja | Gianna Esposito | Lilian M. Tredwin | Nina Goodman | G. Esposito | Varshini Vasudevaraja | A. Iafrate | Andrew S. Chi | Lilian M. Tredwin
[1] Till Acker,et al. DNA methylation-based classification of central nervous system tumours , 2018, Nature.
[2] C. Brennan,et al. Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence , 2017, Nature Genetics.
[3] I. Tabbara,et al. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia , 2017, Annals of Hematology.
[4] Frédérick A. Mallette,et al. Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling. , 2017, Trends in cell biology.
[5] Pedro P. Rocha,et al. Low-Grade Astrocytoma Mutations in IDH1, P53, and ATRX Cooperate to Block Differentiation of Human Neural Stem Cells via Repression of SOX2. , 2017, Cell reports.
[6] Simion I. Chiosea,et al. Frequent IDH2 R172 mutations in undifferentiated and poorly‐differentiated sinonasal carcinomas , 2017, The Journal of pathology.
[7] Steven J. M. Jones,et al. Erratum: Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles (Cell Reports (2017) 18(11) (2780–2794) (S2211124717302140) (10.1016/j.celrep.2017.02.033)) , 2017 .
[8] P. Vertino,et al. Orphan CpG islands define a novel class of highly active enhancers , 2017, Epigenetics.
[9] Chris Sander,et al. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles , 2017, Cell reports.
[10] J. Hornick,et al. Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma , 2017, Modern Pathology.
[11] Julie M. Batten,et al. IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. , 2016, Cancer research.
[12] J. Choi,et al. Frequent hypermethylation of orphan CpG islands with enhancer activity in cancer , 2016, BMC Medical Genomics.
[13] A. Iafrate,et al. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. , 2015, Cancer Cell.
[14] Shawn M. Gillespie,et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas , 2015, Nature.
[15] Darrell,et al. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. , 2015, The oncologist.
[16] M. Konopleva,et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML , 2015, American journal of hematology.
[17] K. Aldape,et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas , 2015, Acta Neuropathologica.
[18] A. Iafrate,et al. Deep sequencing identifies IDH1 R132S mutation in adult medulloblastoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] K. Ross,et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer , 2014, Nature.
[20] Hai Yan,et al. Cancer-associated Isocitrate Dehydrogenase 1 (IDH1) R132H Mutation and d-2-Hydroxyglutarate Stimulate Glutamine Metabolism under Hypoxia* , 2014, The Journal of Biological Chemistry.
[21] Christian M. Metallo,et al. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. , 2014, Cancer research.
[22] P. Pandolfi,et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. , 2014, Cell stem cell.
[23] Benjamin J. Raphael,et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.
[24] Fang Wang,et al. An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells , 2013, Science.
[25] Fang Wang,et al. Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation , 2013, Science.
[26] W. Kaelin,et al. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. , 2013, Genes & development.
[27] David T. W. Jones,et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.
[28] Timothy A. Chan,et al. Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma , 2012, Oncotarget.
[29] Joshua F. McMichael,et al. The Origin and Evolution of Mutations in Acute Myeloid Leukemia , 2012, Cell.
[30] Derek Y. Chiang,et al. Mutations in Isocitrate Dehydrogenase 1 and 2 Occur Frequently in Intrahepatic Cholangiocarcinomas and Share Hypermethylation Targets with Glioblastomas , 2012, Oncogene.
[31] G. Schackert,et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas , 2012, Journal of Neuro-Oncology.
[32] S. Berger,et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.
[33] A. Viale,et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.
[34] A. Futreal,et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2 , 2011, Nature Genetics.
[35] A. Tefferi,et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients , 2011, Leukemia.
[36] Christian M. Metallo,et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia , 2011, Nature.
[37] G. Shadel,et al. Revisiting the TCA cycle: signaling to tumor formation. , 2011, Trends in molecular medicine.
[38] A. Tefferi,et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F , 2011, Leukemia.
[39] A. Grigoriadis,et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours , 2011, The Journal of pathology.
[40] A. Bird,et al. CpG islands and the regulation of transcription. , 2011, Genes & development.
[41] J. Licht,et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.
[42] K. Yen,et al. Cancer-associated IDH mutations: biomarker and therapeutic opportunities , 2010, Oncogene.
[43] Xiao Zhang,et al. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis , 2010, BMC Bioinformatics.
[44] G. Riggins,et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. , 2010, Cancer research.
[45] Michael Heuser,et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis , 2010, Haematologica.
[46] D. Birnbaum,et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms , 2010, Leukemia.
[47] L. Liau,et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.
[48] R. McLendon,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[49] P. Kleihues,et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.
[50] M. Snuderl,et al. Whole Genome DNA Methylation Analysis of Human Glioblastoma Using Illumina BeadArrays. , 2018, Methods in molecular biology.
[51] Richard A. Moore,et al. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. , 2017, Cell reports.
[52] Jeffrey W. Clark,et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. , 2012, The oncologist.